Form 4: Novavax Officer Vests RSUs, Sells Shares for Tax

Novavax officer Ruxandra Draghia-Akli acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Summary

• Ruxandra Draghia-Akli, an officer at Novavax Inc. (NVAX), acquired 14,257 shares of common stock on November 11, 2025, through the vesting and conversion of Restricted Stock Units (RSUs).
• Concurrently, 6,048 shares of common stock were disposed of at a price of $7.40 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Draghia-Akli directly owns 8,209 shares of common stock.
• 14,257 Restricted Stock Units (RSUs) were disposed of as they vested and converted into common stock.
• Draghia-Akli continues to beneficially own 28,513 Restricted Stock Units (RSUs).
• The RSUs vest in one-third (1/3) increments on each of the first three anniversaries of the grant date, contingent on continued employment.

Sentiment

Score: 6

Explanation: The filing details a routine executive compensation event (RSU vesting and tax-related sale). It's neutral in terms of company performance but shows an officer's continued equity stake.

Positives

• Officer Ruxandra Draghia-Akli continues to hold a significant number of unvested Restricted Stock Units (28,513), indicating ongoing alignment with shareholder interests.

Negatives

• The disposition of 6,048 shares of common stock for tax purposes reduces the officer's direct common stock holdings.

Risks

• The vesting of Restricted Stock Units is contingent on continued employment, posing a risk to the officer's full equity realization if employment ceases.

Future Outlook

The remaining 28,513 Restricted Stock Units are scheduled to vest in one-third increments on the first three anniversaries of their grant date, subject to the officer's continued employment.

Industry Context

This Form 4 filing reflects routine equity compensation activity for an executive at a biotechnology company. Such transactions are common for officers receiving Restricted Stock Units as part of their compensation package, with a portion typically sold to cover tax obligations upon vesting.

Comparison to Industry Standards

• The RSU vesting and subsequent tax-related sale are standard practices for executive compensation in the biotechnology and pharmaceutical sectors.
• Companies like Moderna, Pfizer, and Johnson & Johnson frequently use similar equity compensation structures for their executives, where a portion of vested shares is sold to cover statutory tax withholdings.
• The vesting schedule of one-third over three years is also a common industry standard for executive retention and long-term incentive alignment.

Stakeholder Impact

• Shareholders: The officer's continued beneficial ownership of RSUs aligns their interests with long-term shareholder value.
• Employees: The vesting schedule reinforces the importance of continued employment for equity realization.

Next Steps

• Continued vesting of the remaining 28,513 Restricted Stock Units in one-third increments on the first three anniversaries of the grant date, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The officer's continued significant equity holdings (unvested RSUs) suggest ongoing alignment with the company's long-term prospects, but the transaction itself is not a catalyst for a 'buy' or 'sell' decision.

Keywords

Novavax, NVAX, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Officer Transaction, Equity Compensation, Stock Sale, Tax Withholding